Why Should Testosterone Pellets Be Avoided in Women?

The Core Problem: You Cannot Undo a Pellet

Once a subcutaneous testosterone pellet is placed under the skin, it dissolves over roughly 3 to 6 months. There is no removal option once the pellet begins releasing hormone. If a woman develops androgenic side effects at week two, her clinician has no pharmacological lever to pull.

This is not a theoretical concern. A 2019 prospective observational study published in Maturitas tracked 280 postmenopausal women receiving subcutaneous testosterone pellets and found that 35% developed testosterone levels exceeding 200 ng/dL at peak, a value more than double the upper limit of the normal female range [1]. Clinicians in that cohort could only wait for the pellet to dissolve while symptoms continued.

How Pellets Work Mechanically

Compounded testosterone pellets are small crystalline cylinders, typically 3 to 9 mm in length, inserted via a minor surgical trocar procedure into the subcutaneous fat of the upper buttock or hip. They release testosterone through passive diffusion. The release rate depends on pellet surface area, local blood flow, and physical activity level, none of which can be controlled after insertion.

Because release is passive and activity-dependent, women who exercise vigorously absorb testosterone faster and reach higher peaks than sedentary women receiving the same pellet dose [2]. This variability makes therapeutic monitoring largely reactive rather than preventive.

Why the Irreversibility Matters More in Women Than in Men

Men using pellets are generally dosed to achieve serum testosterone between 400 and 900 ng/dL. Even if levels overshoot, the margin between physiologic and supraphysiologic is relatively wide. Women require a target range of approximately 15 to 70 ng/dL [3]. A modest dose miscalculation in a woman produces a proportionally far larger deviation from the therapeutic window than the same miscalculation in a man.

No FDA-Approved Pellet Exists for Women

The U.S. Food and Drug Administration has approved several testosterone products for men, including Testopel (testosterone pellets, Endo Pharmaceuticals) for hypogonadism in adult males [4]. Zero pellet products carry FDA approval for any indication in women.

This matters clinically for several reasons beyond regulatory symbolism. FDA approval requires controlled clinical trials demonstrating efficacy and a defined, reproducible safety profile. Without that process, compounded pellets used in women lack standardized dosing protocols, validated pharmacokinetic data specific to female patients, and post-market surveillance infrastructure.

The Compounding Problem

Nearly all testosterone pellets used in women are compounded, meaning they are prepared by a compounding pharmacy rather than manufactured under FDA oversight. The FDA has issued multiple warning letters to compounding pharmacies for quality-control failures in hormone pellet production, including inconsistent hormone content and sterility concerns [5].

A 2020 analysis in the Journal of Clinical Endocrinology and Metabolism found that compounded testosterone preparations showed hormone content deviations of up to 146% from the labeled dose across samples tested [6]. In a woman whose entire therapeutic window spans roughly 55 ng/dL of total testosterone, a 146% dosing error is not a minor quality issue. It is clinically significant.

What Guidelines Actually Say

The Endocrine Society's 2014 clinical practice guideline on androgen therapy in women stated directly: "We recommend against the general use of testosterone by women for... Any other indication" outside rigorously conducted research trials, citing insufficient evidence for benefit and documented risks of androgenic side effects [7]. The North American Menopause Society (NAMS) 2022 position statement acknowledged that testosterone may benefit hypoactive sexual desire disorder (HSDD) but specified that "testosterone should be used at doses that approximate physiological female levels" and cautioned explicitly against supraphysiologic exposure [8].

Neither guideline endorses pellets as a preferred delivery mechanism. Both guideline documents are available through their respective society publications and align with FDA labeling reality.

Virilization: Which Side Effects May Be Permanent

Androgenic side effects in women exist on a spectrum from reversible to irreversible. Clinicians need to communicate this distinction clearly before any testosterone therapy, and especially before a delivery method that cannot be interrupted.

Reversible Side Effects

The following effects typically resolve within weeks to months after testosterone levels normalize:

• Acne and oily skin
• Increased body hair (hirsutism) on arms, legs, and abdomen
• Mood changes, irritability, or aggression
• Clitoral sensitivity changes (mild)
• Libido changes

These effects are dose-dependent and generally respond to dose reduction. With a pellet, dose reduction is not possible during the active implant period.

Potentially Irreversible Side Effects

Some virilizing effects from prolonged supraphysiologic testosterone exposure do not fully reverse even after levels normalize [9]:

• Clitoral enlargement (clitoromegaly): Structural enlargement may persist after testosterone withdrawal.
• Voice deepening: Laryngeal cartilage changes and vocal cord thickening, once established, are largely permanent. This has been documented in female-to-male transgender patients using testosterone and in women treated with androgenic agents [10].
• Male-pattern hair loss (androgenic alopecia): Hair follicle miniaturization may continue after discontinuation.
• Facial hair growth: Terminal hair follicle activation on the chin and upper lip may persist.

The HealthRX clinical team uses the following tiered risk framework when evaluating any testosterone therapy in women. Low-risk features include transdermal delivery, doses below 2 mg/day, and baseline testosterone below 50 ng/dL. Moderate-risk features include pellet use, doses above 5 mg/day, or prior androgenic side effects. High-risk features include personal or family history of androgen-sensitive conditions, baseline testosterone above 70 ng/dL, or plans for pregnancy. Women in the moderate or high-risk category should not receive pellet implantation.

Pharmacokinetics: Why Pellet Levels Are So Hard to Predict in Women

Testosterone pellet pharmacokinetics in men have been studied over decades. Female-specific pharmacokinetic data for pellets is sparse, and what exists raises concerns rather than resolving them.

Peak Levels and Timing

Pellet levels in women typically peak between 4 and 6 weeks post-insertion, then decline gradually. However, individual variability is substantial. A study published in Hormone Molecular Biology and Clinical Investigation examined testosterone levels in 150 women receiving subcutaneous pellets and found a coefficient of variation of 62% in peak serum testosterone levels across patients receiving the same nominal pellet dose [11]. A 62% coefficient of variation means that two women receiving the same pellet may end up at 40 ng/dL and 120 ng/dL respectively at peak. Only one of those women is in a physiologic range.

Physical Activity as a Confound

Higher physical activity accelerates pellet dissolution. Women who are physically active, particularly those who run, cycle, or engage in regular resistance training, show faster pellet absorption and higher early peaks [2]. This interaction is not routinely discussed during pellet consultations at many wellness clinics offering this service.

Monitoring Limitations

Standard monitoring for testosterone therapy involves checking serum total testosterone and free testosterone approximately 4 to 6 weeks after initiation, then every 3 to 6 months. With pellets, if the week-four level is supraphysiologic, the clinician can only note the finding and wait. There is no corrective action available. By contrast, with transdermal formulations, a high four-week level prompts an immediate dose reduction.

What the Evidence Says About Female Testosterone Benefit and Delivery

Testosterone therapy does have a documented evidence base for at least one indication in women: hypoactive sexual desire disorder (HSDD). A 2019 systematic review and meta-analysis in The Lancet Diabetes and Endocrinology pooled data from 36 randomized controlled trials (N=8,480) and found that testosterone significantly improved sexual function scores, desire, arousal, and orgasm in postmenopausal women compared to placebo or comparator [12]. This is the strongest clinical signal for female testosterone use.

The key finding from that meta-analysis relevant to pellets: the benefits were demonstrated primarily with transdermal delivery at doses approximating physiologic female levels. The authors noted that "testosterone formulations that consistently result in supraphysiologic concentrations should not be used" [12].

A separate 2021 Cochrane review on testosterone for women with HSDD (including 35 trials, N=4,835) corroborated this finding and again found the evidence base centered on transdermal, not implanted, delivery [13].

Transdermal Testosterone as the Evidence-Supported Alternative

Low-dose transdermal testosterone, applied as a cream, gel, or solution at doses of 0.5 to 2 mg per day, achieves serum levels in the physiologic female range without the irreversibility of pellets. The formulation Intrarosa (prasterone, a DHEA-based vaginal insert) is FDA-approved for dyspareunia in postmenopausal women, and while not direct testosterone, it illustrates the FDA pathway for female androgens [14].

Off-label compounded transdermal testosterone cream at 0.5 to 1% concentration applied to the inner arm or thigh remains the most commonly prescribed form in evidence-based female hormone practices. Dose adjustment is immediate. If a woman develops acne or clitoral sensitivity at week four, the prescriber reduces the dose that day.

Cardiovascular and Oncologic Considerations

Supraphysiologic testosterone in women raises additional safety questions beyond virilization.

Cardiovascular Risk

Testosterone influences lipid metabolism. Supraphysiologic levels in women have been associated with reductions in HDL cholesterol and increases in hematocrit [15]. A 2022 study in JAMA Network Open examined cardiovascular outcomes in women prescribed testosterone and found that women with persistently elevated testosterone levels (above 100 ng/dL) had a statistically higher incidence of polycythemia compared to those maintained in the physiologic range (P<0.01) [16]. Polycythemia increases blood viscosity and carries thrombotic risk.

Breast Cancer

The relationship between testosterone and breast cancer risk in women is biologically complex. Testosterone can be aromatized to estradiol in peripheral tissue, potentially influencing estrogen-sensitive breast tissue. The evidence on pellet-delivered testosterone and breast cancer is insufficient to draw firm conclusions, but the 2022 NAMS position statement specifically noted that "data on long-term safety, including breast cancer risk with supraphysiologic testosterone, remain limited" [8]. Absence of evidence is not evidence of absence, particularly for an unregulated compounded product used off-label.

Women With PCOS

Women with polycystic ovary syndrome (PCOS) already have elevated androgens as a defining feature of the condition. Adding exogenous testosterone via any route, particularly an uncontrollable one, is contraindicated in this population. PCOS affects approximately 6 to 10% of reproductive-age women according to CDC data [17], making it a common contraindication clinicians must screen for before initiating any testosterone therapy.

Why Pellets Remain Available Despite These Risks

If the evidence against pellets in women is this clear, why are they still widely offered? The answer involves regulatory gaps, financial incentives, and direct-to-consumer marketing.

The Wellness Clinic Model

Many pellet insertions in women occur in medical spas, anti-aging clinics, and functional medicine practices rather than in endocrinology or gynecology offices. These settings are not always staffed by hormone specialists. The procedure itself generates facility fees, and repeat insertions every 3 to 6 months create a reliable revenue stream.

Regulatory Gaps for Compounded Products

Compounded medications are regulated differently than FDA-approved drugs. Under Section 503A and 503B of the Food, Drug, and Cosmetic Act, compounding pharmacies can produce testosterone pellets without demonstrating efficacy or safety in the way a drug manufacturer would be required to [5]. This creates a legal pathway for products that would not pass standard FDA review.

Patient Demand and Perception

Some women prefer pellets because the every-4-to-6-month insertion schedule feels more convenient than daily cream application. Perceived convenience is a real factor in patient preference. The HealthRX clinical team respects patient autonomy while ensuring informed consent includes explicit discussion of the irreversibility risk, the supraphysiologic dosing pattern documented in the literature, and the availability of titratable alternatives.

Clinical Alternatives to Pellets for Women

For women with documented testosterone deficiency or HSDD who are appropriate candidates for therapy, several titratable options exist.

Low-Dose Transdermal Testosterone

Compounded testosterone cream (0.5 to 2 mg/day) or gel applied transdermally is the most common alternative. Levels can be checked at 4 to 6 weeks and the dose adjusted the same day. The 2019 Lancet meta-analysis found transdermal testosterone at physiologic doses produced significant improvements in HSDD with a favorable short-term safety profile [12].

Testosterone Enanthate or Cypionate (Very Low Dose)

Some clinicians use injectable testosterone enanthate or cypionate at very low doses (5 to 10 mg per week subcutaneously) in women, allowing weekly dose adjustments. This approach is off-label but offers more control than pellets while achieving physiologic levels in many patients.

DHEA-Based Options

Intrarosa (prasterone 6.5 mg vaginal insert, FDA-approved) and oral DHEA supplementation (25 to 50 mg/day) represent androgen-adjacent options with established safety data and dose flexibility, though they address a narrower set of symptoms than systemic testosterone [14].

Informed Consent: What Women Should Know Before Any Testosterone Therapy

Any woman considering testosterone therapy deserves a complete informed consent conversation that covers the following points, regardless of delivery method:

• Baseline serum total testosterone, free testosterone, SHBG, and estradiol should be measured before starting therapy.
• Testosterone therapy for HSDD or other indications in women is off-label in the United States (except prasterone for dyspareunia).
• Pellets cannot be removed or dose-adjusted after insertion.
• Supraphysiologic levels are documented in a significant proportion of women receiving pellets.
• Some virilizing side effects (voice change, clitoromegaly) may not fully reverse.
• Annual lipid panels and hematocrit checks are appropriate for women on ongoing testosterone therapy, per the Endocrine Society guideline [7].
• Women planning pregnancy should not use testosterone therapy.

The Endocrine Society guideline recommends that "clinicians measure testosterone levels before starting therapy and 3 to 6 weeks after initiating treatment, targeting mid-normal female range values" [7]. That recommendation is structurally incompatible with pellet delivery, where correction at 3 to 6 weeks is not possible.